Satellos Bioscience's Phase 2 Data Readout Could Drive Significant Upside, Oppenheimer Says
Satellos Bioscience: Q3 Earnings Snapshot
Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress
Satellos Bioscience Q3 EPS $(0.53) Beats $(0.56) Estimate
Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
Satellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
Satellos to Participate in Upcoming Investor Conferences
Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
Satellos Granted Composition of Matter Patent for Forazapadin
Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
Satellos Bioscience Completes Enrollment in Phase 2 Basecamp Trial
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age
Satellos Receives FDA Clearance For FSHD Investigational New Drug Application
Satellos Receives FDA Clearance to Study Forazapadin in FSHD
Satellos stock jumps after FDA clears FSHD trial for forazapadin
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.